United States Food and Drug Administration (USFDA) has inspected Lupin’s Mandideep Unit-1 facility from November 14, 2022 to November 23, 2022. The inspection of the facility closed with issuance of a Form 483 with eight observations each for the drug product facility and API facility at the site.
The company is committed to addressing the observations and will work with the USFDA to resolve these issues at the earliest. The company is uphold quality and compliance issues with utmost importance and remain committed to be compliant with cGMP quality standards across all our facilities.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1787.10 |
| Dr. Reddys Lab | 1271.75 |
| Cipla | 1376.25 |
| Zydus Lifesciences | 1097.90 |
| Lupin | 2248.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: